3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 4
2
Phase 3
2
Phase 2/3
2
Phase 1/2
2
Phase 1
2
Phase EARLY_PHASE1
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Melanoma
2
Melanoma, Cutaneous Malignant
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Dacarbazine
25
Nivolumab
24
pembrolizumab
19
Ipilimumab
18
Interferon-alpha
10
trametinib
8
Vemurafenib
8
dabrafenib
7
aldesleukin
7
Temozolomide
7
Introns
7
Interferon alpha-2
6
Interleukin-2
5
Cisplatin
5
Chemotherapy, Adjuvant
5
talimogene laherparepvec
4
cemiplimab
4
binimetinib
4
Radiotherapy
4
Paclitaxel
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
sargramostim
3
encorafenib
3
cobimetinib
3
Vinblastine
3
Surgical Procedures, Operative
3
Specimen Handling
3
Sodium Chloride
3
Radiosurgery
3
Opdualag
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Melanoma
×
relatlimab
×
Clear all
NCT05625399
2026-06-03
RELATIVITY-127
Bristol-Myers Squibb
Phase 3
Active not recruiting
579 enrolled
NCT05002569
2026-01-08
RELATIVITY-098
Bristol-Myers Squibb
Phase 3
Terminated
1,093 enrolled
15 charts